Harald Grut

Dr. Harald Grut


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SDSvein Dueland
Svein Dueland
HGHarald Grut
Harald Grut
TSTrygve Syversveen
Trygve Syversveen
MHMorten Hagness
Morten Hagness
PLPål-Dag Line
Pål-Dag Line
Patients with non‐resectable colorectal cancer receiving palliative chemotherapy has a 5‐year overall survival of about 10%. Liver transplantation provided Kaplan‐Meier estimated 5‐year overall survival of up to 83%. The objective of the study was to evaluate the ability of different scoring systems to warrant long term overall survival after liver transplantation. Colorectal cancer patients with non‐resectable liver only metastases determined by CT/MRI/PET‐CT scans from two prospective studies (SECA‐I and II) were included. All included patients had previously received chemotherapy. PET/CT was performed within 90 days of the liver transplantation. Overall survival, disease‐free survival and survival after relapse based on the following scoring systems; Fong Clinical Risk Score, total PET liver uptake (metabolic tumor volume) and Oslo Score were compared. At median follow‐up of 85 months of patients alive, Kaplan‐Meier overall survival at five years were 100%, 78% and 67%, in patients with Fong Clinical Risk Score 0‐2, metabolic tumor volume‐low group and Oslo Score 0‐2, respectively. Median overall survival was 101 months, 68 months and 65 months in Fong Clinical Risk Score 0‐2, metabolic tumor volume‐low and Oslo Score 0‐2. These selection criteria may be used to obtain 5‐year overall survival rates comparable to other indications for liver transplantation.

25 April 2020 in BJS Open
Verified
Journal Article
Open access
PDF file
Tor Magnus SmedmanTor Magnus Smedman
Tor Magnus Smedman
PLP.‐D. Line
P.‐D. Line
MHM. Hagness
M. Hagness
TST. Syversveen
T. Syversveen
HGHarald Grut
Harald Grut
SDSvein Dueland
Svein Dueland
Background Patients with metastatic colorectal cancer receiving palliative chemotherapy have a 5‐year survival rate of approximately 10 per cent. Liver transplantation using strict selection criteria in patients with colorectal cancer and unresectable liver‐only disease will result in a 5‐year survival rate of 56–83 per cent. The aim of this study was to evaluate survival of patients with colorectal liver metastases (CRLM) after liver transplantation using extended criteria for both patients and donors. Methods This was a prospective single‐arm study. Patients with synchronous unresectable CRLM who were not suitable for arms A, B or C of the SEcondary CAncer (SECA) II study who had undergone radical resection of the primary tumour and received chemotherapy were included; they underwent liver transplantation with extended criteria donor grafts. Patients who had resectable pulmonary metastases were eligible for inclusion. The main exclusion criteria were BMI above 30 kg/m2 and liver metastases larger than 10 cm. Survival was estimated using Kaplan–Meier analysis. Results Ten patients (median age 54 years; 3 women) were included. They had an extensive liver tumour load with a median of 20 (range 1–45) lesions; the median size of the largest lesion was 59 (range 15–94) mm. Eight patients had (y)pN2 disease, six had poorly differentiated or signet ring cell‐differentiated primary tumours, and five had primary tumour in the ascending colon. The median Fong clinical risk score was 3 (range 2–5) and the median Oslo score was 1 (range 1–4). The median plasma carcinoembryonic antigen level was 4·3 (range 2–4346) μg/l. Median disease‐free and overall survival was 4 and 18 months respectively. Conclusion Patients with unresectable liver‐only CRLM undergoing liver transplantation with extended patient and donor criteria have relatively short overall survival.

1 February 2018 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
HGHarald Grut
Harald Grut
SSS. Solberg
S. Solberg
TST. Seierstad
T. Seierstad
MRM E Revheim
M E Revheim
TET. S. Egge
T. S. Egge
SDSvein Dueland
Svein Dueland

12 October 2017 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
HGHarald Grut
Harald Grut
SDSvein Dueland
Svein Dueland
PLPål Dag Line
Pål Dag Line
MRMona Elisabeth Revheim
Mona Elisabeth Revheim

14 October 2022 in Annals of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
HGHarald Grut
Harald Grut
PLPål-Dag Line
Pål-Dag Line
TSTrygve Syversveen
Trygve Syversveen
SDSvein Dueland
Svein Dueland
Objective: To report 15 years of experience with metabolic tumor volume (MTV) of liver metastases from the preoperative 18F-FDG PET/CT to predict long-term survival after liver transplantation (LT) for unresectable colorectal liver metastases (CRLM). Methods: The preoperative 18F-FDG PET/CT from all SECA 1 and 2 patients was evaluated. MTV was obtained from all liver metastases. The patients were divided into one group with low MTV (< 70 cm3) and one group with high MTV (> 70 cm3) based on a receiver operating characteristic analysis. Overall survival (OS), disease-free survival (DFS) and post recurrence survival (PRS) for patients with low versus high MTV were compared using the Kaplan–Meier method and log rank test. Clinopathological features between the two groups were compared by a nonparametric Mann–Whitney U test for continuous and Fishers exact test for categorical data. Results: At total of 40 patients were included. Patients with low MTV had significantly longer OS (p < 0.001), DFS (p < 0.001) and PRS (p = 0.006) compared to patients with high values. The patients with high MTV had higher CEA levels, number of liver metastases, size of the largest liver metastasis, N-stage, number of chemotherapy lines and more frequently progression of disease at LT compared to the patients with low MTV. Conclusion: MTV of liver metastases is highly predictive of long-term OS, DFS and PRS after LT for unresectable CRLM and should be implemented in risk stratification prior to LT.

1 July 2018 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
HGHarald Grut
Harald Grut
MRMona-Elisabeth Revheim
Mona-Elisabeth Revheim
PLPål-Dag Line
Pål-Dag Line
SDSvein Dueland
Svein Dueland
Objective The aim of this study was to evaluate fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT for the selection of patients with nonresectable colorectal liver metastases (NCLM) for liver transplantation (LT). In the secondary cancer study, we reported an improved 5-year overall survival in patients treated with LT for NCLM (56%) compared with chemotherapy (9%). However, many patients were rejected for LT owing to the detection of extrahepatic disease at preoperative imaging. Patients and methods 18F-FDG PET/CT and contrast-enhanced computed tomography (ceCT) examinations before tentative LT for NCLM were assessed, and findings contraindicating LT were registered. Maximum, mean and peak standardized uptake values; tumor-to-background ratio; metabolic tumor volume; and total lesion glycolysis were measured and calculated for all liver metastases. Overall survival was calculated by the Kaplan–Meier method. Results Thirty-two patients excluded by 18F-FDG PET/CT and/or ceCT before tentative LT for NCLM were identified. 18F-FDG PET/CT from 20 of the 32 excluded patients revealed extrahepatic disease. Eight of the other 12 patients had a negative 18F-FDG PET/CT finding but were excluded by ceCT. Ten patients were excluded by 18F-FDG PET/CT only. Four patients were excluded owing to detected malignancy from frozen sections at the start of the intended transplant operation. Tumor-to-background ratio of the liver metastases was significantly higher in patients where 18F-FDG PET/CT detected extrahepatic disease (P=0.03). The median (range) survival after exclusion was 16 (0–52) months. Conclusion The ability of 18F-FDG PET/CT to detect extrahepatic disease before LT for NCLM is vital to establish LT as a treatment option.